Myriad Genetics (MYGN) Q3 Earnings and Revenues Surpass Estimates

Myriad Genetics (MYGN) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of$ 0.02 per share. This compares to loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 200%. A quarter ago, it was expected that this molecular diagnostic company would post a loss of$ 0.01 per share when it actually produced earnings of $0.05, delivering a surprise of 600%.Over the last four quarters, t ...